{"id":54879,"date":"2023-03-15T21:03:27","date_gmt":"2023-03-15T20:03:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/"},"modified":"2023-03-15T21:03:27","modified_gmt":"2023-03-15T20:03:27","slug":"adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/","title":{"rendered":"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022"},"content":{"rendered":"
\n

LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d).\n<\/p>\n

<\/a><\/p>\n

\nADC Therapeutics\u2019 Annual Report on Form 20-F can be accessed by visiting either the SEC\u2019s website at www.sec.gov<\/a> or the Investors section of the Company\u2019s website at ir.adctherapeutics.com<\/a>. In addition, shareholders may request a hard copy of the Company\u2019s audited financial statements, or its complete Annual Report on Form 20-F which include the audited financial statements, free of charge, by contacting IR@adctherapeutics.com<\/a>.\n<\/p>\n

\nAbout ADC Therapeutics<\/b>\n<\/p>\n

\nADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.\n<\/p>\n

\nADC Therapeutics\u2019 CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.\n<\/p>\n

\nADC Therapeutics is based in Lausanne (Biop\u00f4le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https:\/\/adctherapeutics.com\/<\/a> and follow the Company on Twitter<\/a> and LinkedIn<\/a>.\n<\/p>\n

\nZYNLONTA\u00ae<\/sup> is a registered trademark of ADC Therapeutics SA.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company\u2019s ability to achieve the 2023 net product sales guidance for ZYNLONTA\u00ae<\/sup> and the decrease in total operating expenses for 2023 and 2024, the expected cash runway into the middle of 2025, the Company\u2019s ability to continue to commercialize ZYNLONTA\u00ae<\/sup> in the United States and future revenue from the same; Swedish Orphan Biovitrum AB (Sobi\u00ae<\/sup>) ability to successfully commercialize ZYNLONTA\u00ae<\/sup> in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; our strategic partners\u2019, including Mitsubishi Tanabe Pharma Corporation and Overland Pharmaceuticals, ability to obtain regulatory approval for ZYNLONTA\u00ae<\/sup> in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the Company\u2019s ability to market its products in compliance with applicable laws and regulations; the Company\u2019s expectations regarding the impact of the Infrastructure Investment and Jobs Act; the timing and results of the Company\u2019s or its partners\u2019 research projects or clinical trials including LOTIS 2, 5 and 9, ADCT 901, 601 and 212, the timing and outcome of regulatory submissions and actions by the FDA or other regulatory agencies with respect to the Company\u2019s products or product candidates; projected revenue and expenses; the Company\u2019s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company\u2019s activities by such indebtedness, the ability to repay such indebtedness and the significant cash required to service such indebtedness; the Company\u2019s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as \u201cmay\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201cwould\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cestimate\u201d, \u201cpredict\u201d, \u201cpotential\u201d, \u201cseem\u201d, \u201cseek\u201d, \u201cfuture\u201d, \u201ccontinue\u201d, or \u201cappear\u201d or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the \u201cRisk Factors\u201d section of the Company’s Annual Report on Form 20-F and in the Company’s other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. The Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/strong>\n<\/p>\n

\nEugenia Litz
\n
ADC Therapeutics
\n
Eugenia.Litz@adctherapeutics.com<\/a>
+44 7879 627205\n<\/p>\n

\nAmanda Loshbaugh
\n
ADC Therapeutics
\n
Amanda.Loshbaugh@adctherapeutics.com<\/a>
+1 917-288-7023\n<\/p>\n

\nMedia<\/strong>\n<\/p>\n

\nMary Ann Ondish
\n
ADC Therapeutics
\n
Maryann.Ondish@adctherapeutics.com<\/a>
+1 914-552-4625\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d). ADC Therapeutics\u2019 Annual Report on Form 20-F can be accessed by visiting either the SEC\u2019s website at www.sec.gov or the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54879","6":"format-standard","7":"category-industry"},"yoast_head":"\nADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d). ADC Therapeutics\u2019 Annual Report on Form 20-F can be accessed by visiting either the SEC\u2019s website at www.sec.gov or the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T20:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230315005747\/en\/1739598\/21\/ADCT_4C_TM_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022\",\"datePublished\":\"2023-03-15T20:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/\"},\"wordCount\":818,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005747\\\/en\\\/1739598\\\/21\\\/ADCT_4C_TM_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/\",\"name\":\"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005747\\\/en\\\/1739598\\\/21\\\/ADCT_4C_TM_%282%29.jpg\",\"datePublished\":\"2023-03-15T20:03:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005747\\\/en\\\/1739598\\\/21\\\/ADCT_4C_TM_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005747\\\/en\\\/1739598\\\/21\\\/ADCT_4C_TM_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/","og_locale":"en_US","og_type":"article","og_title":"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 - Pharma Trend","og_description":"LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d). ADC Therapeutics\u2019 Annual Report on Form 20-F can be accessed by visiting either the SEC\u2019s website at www.sec.gov or the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-15T20:03:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230315005747\/en\/1739598\/21\/ADCT_4C_TM_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022","datePublished":"2023-03-15T20:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/"},"wordCount":818,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230315005747\/en\/1739598\/21\/ADCT_4C_TM_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/","url":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/","name":"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230315005747\/en\/1739598\/21\/ADCT_4C_TM_%282%29.jpg","datePublished":"2023-03-15T20:03:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230315005747\/en\/1739598\/21\/ADCT_4C_TM_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230315005747\/en\/1739598\/21\/ADCT_4C_TM_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/adc-therapeutics-releases-its-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54879"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54879\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}